CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down

Corcept Therapeutics (CORT) reported Q2 EPS of $0.29, surpassing estimates, but Q2 revenues of $194.4 million missed expectations, prompting a significant cut to its 2025 revenue guidance from $900-$950 million to $850-$900 million, which led to a 4.7% pre-market stock decline. Despite the financial miss and lowered outlook, the company highlighted substantial pipeline progress, including a recent New Drug Application (NDA) submission for relacorilant in platinum-resistant ovarian cancer based on positive Phase III ROSELLA study results, alongside an existing NDA for relacorilant in Cushing's syndrome with a December 2025 PDUFA date.

Analysis

Corcept Therapeutics (CORT) presented a mixed second-quarter 2025 report, where an earnings per share of $0.29 beat consensus estimates of $0.23 but was overshadowed by significant headwinds. Quarterly revenues, while up 18.7% year-over-year to $194.4 million, fell short of the $204 million consensus estimate, prompting the company to lower its full-year 2025 revenue guidance to a range of $850-$900 million from a prior $900-$950 million. This guidance cut, which positions the consensus estimate of $899 million at the high end of the new range, triggered a 4.7% pre-market stock decline. The company's financial profile is also under pressure from escalating costs, with selling, general, and administrative expenses rising 55.1% and total operating expenses increasing 30.8% year-over-year. The cash position also weakened, declining to $515 million from $570.8 million in the previous quarter. Offsetting these near-term financial concerns is substantial progress in its clinical pipeline. The company recently submitted a New Drug Application (NDA) for its lead candidate, relacorilant, in platinum-resistant ovarian cancer, supported by positive data from the pivotal phase III ROSELLA study. This is in addition to a previously submitted NDA for relacorilant in Cushing's syndrome, which has a PDUFA target action date of December 30, 2025, creating a clear catalyst path for the company.

Key Decisions for Investors

• Investors should scrutinize the drivers behind the revenue miss and the substantial 55.1% year-over-year increase in SG&A expenses, as these metrics are pressuring near-term profitability and prompted the downward revision of 2025 guidance.
• The investment thesis is heavily weighted towards future pipeline success, so key catalysts to monitor are any FDA communications regarding the two separate NDAs for relacorilant, especially ahead of the December 30, 2025 PDUFA date for its Cushing's syndrome indication.
• Given the stock's negative reaction to the guidance cut, investors might consider the current valuation in the context of both the immediate financial headwinds and the long-term growth potential from potential approvals of relacorilant for two distinct indications.